Logo image of ARPO

Aerpio Pharmaceuticals Inc (ARPO) Stock Fundamental Analysis

NASDAQ:ARPO - Nasdaq -

2.2  -0.02 (-0.9%)

After market: 2.28 +0.08 (+3.64%)

Fundamental Rating

2

ARPO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While ARPO seems to be doing ok healthwise, there are quite some concerns on its profitability. ARPO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARPO had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -49.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARPO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

There is no outstanding debt for ARPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ARPO has an Altman-Z score of 22.17. This indicates that ARPO is financially healthy and has little risk of bankruptcy at the moment.
ARPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.17
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ARPO has a Current Ratio of 16.94. This indicates that ARPO is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 16.94 indicates that ARPO has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94

More info and screens

1

3. Growth

3.1 Past

ARPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -355.56%.
The Revenue for ARPO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.84% on average over the next years. This is quite good.
Based on estimates for the next years, ARPO will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y33.81%
EPS Next 2Y6.46%
EPS Next 3Y34.35%
EPS Next 5Y14.84%
Revenue Next Year-100%
Revenue Next 2Y-56.22%
Revenue Next 3Y-41.69%
Revenue Next 5Y-14.87%

3.3 Evolution

ARPO Yearly Revenue VS EstimatesARPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2022 2023 2024 5M 10M 15M 20M
ARPO Yearly EPS VS EstimatesARPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARPO Price Earnings VS Forward Price EarningsARPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.12
ARPO Per share dataARPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

ARPO's earnings are expected to grow with 34.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y34.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aerpio Pharmaceuticals Inc

NASDAQ:ARPO (8/26/2021, 8:07:55 PM)

After market: 2.28 +0.08 (+3.64%)

2.2

-0.02 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners1.31%
Ins Owner Change0%
Market Cap104.85M
Analysts100
Price Target47.94 (2079.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB N/A
EV/EBITDA -3.12
EPS(TTM)-0.4
EYN/A
EPS(NY)-27.85
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.74
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z 22.17
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
EPS Next Y33.81%
EPS Next 2Y6.46%
EPS Next 3Y34.35%
EPS Next 5Y14.84%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-56.22%
Revenue Next 3Y-41.69%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A